- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04224506
A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
September 2, 2021 updated by: ProgenaBiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to Myasthenia Gravis.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Ventura, California, United States, 93003
- Recruiting
- ProgenaBiome
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Myasthenia Gravis
Description
Inclusion Criteria:
Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent
- Male or female of all ages.
- Diagnosis of Myasthenia Gravis by a physician
Exclusion Criteria:
- Refusal to sign informed consent form
- History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
- Postoperative stoma, ostomy, or ileoanal pouch
- Participation in any experimental drug protocol within the past 12 weeks
- Treatment with total parenteral nutrition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Myasthenia Gravis
Patients who have been diagnosed with Myasthenia Gravis.
|
There is no intervention for this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing
Time Frame: Three years
|
Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome.
These data will then be categorized with Myasthenia Gravis.
|
Three years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sabine Hazan, ProgenaBiome
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 2, 2020
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
July 1, 2023
Study Registration Dates
First Submitted
January 8, 2020
First Submitted That Met QC Criteria
January 8, 2020
First Posted (Actual)
January 13, 2020
Study Record Updates
Last Update Posted (Actual)
September 5, 2021
Last Update Submitted That Met QC Criteria
September 2, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
Other Study ID Numbers
- PRG-039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
There is no plan to share IPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
COUR Pharmaceutical Development Company, Inc.Not yet recruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of Missouri-ColumbiaUniversity of Kansas Medical CenterRecruitingGeneralized Myasthenia GravisUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia GravisChina, United States, Spain, United Kingdom, Korea, Republic of, Italy, Germany, Japan, Brazil, France, Netherlands, Taiwan, Turkey, Israel, Poland, Austria, Denmark, Portugal, Canada, Serbia, Argentina, Switzerland
-
Immunovant Sciences GmbHRecruitingGeneralized Myasthenia GravisUnited States, Poland, Romania, Italy, Georgia, Korea, Republic of, Canada, Japan, Hungary, Spain, Serbia, Germany
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of PittsburghCompletedChronic Low Back PainUnited States